Related references
Note: Only part of the references are listed.ESC 2022 guidelines on cardio-oncology in collaboration with the European Hematology Association (EHA), European Society of Therapeutic Radiology and Oncology (ESTRO) and International Cardio-Oncology Society (IC- OS) developed by the Cardio-Oncology Task Force of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
GIORNALE ITALIANO DI CARDIOLOGIA (2023)
Genetic inhibition of nuclear factor of activated T-cell c2 prevents atrial fibrillation in CREM transgenic mice
Li Ni et al.
CARDIOVASCULAR RESEARCH (2022)
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Craig J. Beavers et al.
CIRCULATION (2022)
Validation of Embolic and Bleeding Risk Scores in Patients With Atrial Fibrillation and Cancer
Sergio Raposeiras-Roubin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2022)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
EUROPEAN HEART JOURNAL (2022)
Safety of catheter ablation of atrial fibrillation in cancer survivors
Michela Giustozzi et al.
JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY (2021)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study
Hyo-Jeong Ahn et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Mechanisms underlying pathological Ca2+ handling in diseases of the heart
Satadru K. Lahiri et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2021)
Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients With Cancer
Toshiaki Isogai et al.
AMERICAN JOURNAL OF CARDIOLOGY (2021)
Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis
Haotian Ma et al.
CARDIOVASCULAR THERAPEUTICS (2021)
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study
Lorena Carballo-Folgoso et al.
LIVER INTERNATIONAL (2021)
INFLUENCE OF ACTIVE CARDIOMONITORING ON THE OVERALL SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOLEUKEMIA RECEIVING IBRUTINIB
E Emelina et al.
HEMATOLOGICAL ONCOLOGY (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents JACC State-of-the-Art Review
Vijay U. Rao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Implantable loop recorder detection of atrial fibrillation to prevent stroke ( The LOOP Study): a randomised controlled trial
Jesper H. Svendsen et al.
LANCET (2021)
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants A Nationwide Cohort Study
Yi-Hsin Chan et al.
STROKE (2021)
Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases
Yuhong Zhai et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2021)
Calmodulin kinase II regulates atrial myocyte late sodium current, calcium handling, and atrial arrhythmia
Amara Greer-Short et al.
HEART RHYTHM (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis
Ilaria Cavallari et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies
Mohamed Elmeliegy et al.
CLINICAL PHARMACOKINETICS (2020)
Immunotherapy-mediated valvulitis: a new cardiovascular immunotherapy-related adverse event
Heba Wassif et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2020)
Loss of SPEG Inhibitory Phosphorylation of Ryanodine Receptor Type-2 Promotes Atrial Fibrillation
Hannah M. Campbell et al.
CIRCULATION (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
Daniel Caldeira et al.
PLOS ONE (2019)
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy
Michael G. Fradley et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium
Le Jiang et al.
HEART RHYTHM (2019)
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH
Aurelien Delluc et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Incidence and complications of perioperative atrial fibrillation after non-cardiac surgery for malignancy
Satoshi Higuchi et al.
PLOS ONE (2019)
Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
Zi-Yi Xu et al.
ONCOTARGETS AND THERAPY (2019)
Atrial Fibrillation in the Era of Emerging Cancer Therapies
Avirup Guha et al.
EUROPEAN HEART JOURNAL (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists
Marc Sorigue et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society (vol 74, pg 104, 2019)
C. T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
High incidence of atrial fibrillation in patients treated with ibrutinib
Florian Baptiste et al.
OPEN HEART (2019)
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
Susan O'Brien et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
Michaela Poliakova et al.
MOLECULAR CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy
Lynne Postovit et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer
Maria D'Souza et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
Xinyu Yang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Managing thrombosis in cancer patients
Tzu-Fei Wang et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Risk of Arterial Thromboembolism in Patients With Cancer
Babak B. Navi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P. B. Chapman et al.
ANNALS OF ONCOLOGY (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Cancer Treatment-Induced Arrhythmias Focus on Chemotherapy and Targeted Therapies
Vitaly Buza et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate
Yu Chen et al.
CARDIOVASCULAR RESEARCH (2017)
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Steven E. Coutre et al.
CLINICAL CANCER RESEARCH (2017)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
Hesham M. Korashy et al.
TOXICOLOGY LETTERS (2016)
Chemotherapy-Induced Valvular Heart Disease
Michael H. Crawford
JACC-CARDIOVASCULAR IMAGING (2016)
Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation
David Conen et al.
JAMA CARDIOLOGY (2016)
Association between Postoperatively Developed Atrial Fibrillation and Long-Term Mortality after Esophagectomy in Esophageal Cancer Patients: An Observational Study
Ji-Hyun Chin et al.
PLOS ONE (2016)
Relation Between Cancer and Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study)
Wesley T. O'Neal et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
Juan Tamargo et al.
DRUG SAFETY (2015)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Ryanodine Receptor-Mediated Calcium Leak Drives Progressive Development of an Atrial Fibrillation Substrate in a Transgenic Mouse Model
Na Li et al.
CIRCULATION (2014)
Worldwide Epidemiology of Atrial Fibrillation A Global Burden of Disease 2010 Study
Sumeet S. Chugh et al.
CIRCULATION (2014)
Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation A Randomized Clinical Trial
Vivek Y. Reddy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Insights Into Onco-Cardiology Atrial Fibrillation in Cancer
Dimitrios Farmakis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Atrial Fibrillation as a Marker of Occult Cancer
Eva B. Ostenfeld et al.
PLOS ONE (2014)
Calcium dysregulation in atrial fibrillation: the role of CaMKII
Jordi Heijman et al.
FRONTIERS IN PHARMACOLOGY (2014)
Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060
Bouwe P. Krijthe et al.
EUROPEAN HEART JOURNAL (2013)
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
Iacopo Petrini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Inhibition of CaMKII Phosphorylation of RyR2 Prevents Induction of Atrial Fibrillation in FKBP12.6 Knockout Mice
Na Li et al.
CIRCULATION RESEARCH (2012)
The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities
Stanley Nattel et al.
EUROPEAN HEART JOURNAL (2012)
Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study
Rune Erichsen et al.
INTERNAL AND EMERGENCY MEDICINE (2012)
Regulation of the Src Family Kinases by Csk
Masato Okada
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study
Andrea Imperatori et al.
JOURNAL OF CARDIOTHORACIC SURGERY (2012)
CaMKII regulation of the cardiac ryanodine receptor and sarcoplasmic reticulum calcium release
Xander H. T. Wehrens
HEART RHYTHM (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?
Ranran Zhang et al.
LEUKEMIA & LYMPHOMA (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases
Kim K. Ia et al.
GROWTH FACTORS (2010)
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition A Meta-Analysis
Markus P. Schneider et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
A. J. Rose et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Calmodulin Kinase II, Sarcoplasmic Reticulum Ca2+ Leak, and Atrial Fibrillation
Dobromir Dobrev et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2010)
Introducing a new entity: chemotherapy-induced arrhythmia
Maya Guglin et al.
EUROPACE (2009)
First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation
Stefano Guzzetti et al.
INTERNAL AND EMERGENCY MEDICINE (2008)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effectiveness of warfarin among patients with cancer
Adam J. Rose et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2007)
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Yoko Miyasaka et al.
CIRCULATION (2006)
Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: Potential role for early remodeling in atrial fibrillation
N Gassanov et al.
CELL CALCIUM (2006)
Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer
CW Siu et al.
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2005)
Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: Analysis of 2588 patients
AA Vaporciyan et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Colorectal cancer and atrial fibrillation:: A case-control study
S Guzzetti et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Share Paper
